Bold Moves

Transform our go-to-market model

Deliver first-in-class science

AMR Action Fund to help stimulate new antibiotic development to address this serious and growing public health threat

The COVID-19 pandemic which no one could have anticipated has reinforced the need to prepare for future global health threats now. This need extends beyond the pandemic to other serious global public health threats such as antimicrobial resistance (AMR).

Unlike COVID-19, AMR is a threat Pfizer saw coming, and the company has been working to combat it for years. It is predictable and preventable, but Pfizer must act now to help stop the spread.


Each year, 700,000 people die from AMR.2

​​​​Antibiotics revolutionized medicine in the 20th century. Together with vaccination, they have led to the near elimination of serious threats from many infectious diseases worldwide. But, over time, bacteria change and adapt to the use of antibiotics, rendering them less effective. This makes it more difficult to treat common infections, leading to longer hospital stays, higher medical costs and increased mortality.

Without action, AMR could lead to the deaths of 10 million people annually by 2050.2

New antibiotics are needed to help combat this growing threat. Unfortunately, the current development pipeline is lacking due to steep development costs, high risk of failure, long lead times and limited market potential – among other obstacles.

Enter the AMR Action Fund.

Pfizer joined more than 20 biopharmaceutical companies who are teaming up to fight back against the growing health threat of AMR. The Fund expects to invest more than $1 billion into the development of novel antibiotics with the goal of bringing two to four new antibiotics to patients by the end of the decade. Pfizer is proud of our $100 million pledge to support this important and groundbreaking industry-led initiative.

Video provided by the AMR Action Fund.

AMR spreads far and quickly, impacting people of any age and in any country – particularly those who are already facing health care inequalities and those with underlying health conditions. In addition to the human toll, the economic impact of AMR could be significant, and requires strong public health and prevention strategies.

Pfizer is proud of its legacy of fighting AMR and plans to continue investing in the ATLAS surveillance platform, the anti-infectives portfolio, and efforts in vaccines – which can help prevent AMR by stopping infections before they start.

The AMR Action Fund is a prime example of innovative thinking, collaboration and action to foster forward-looking, sustainable solutions. Pfizer’s participation is a natural extension of our commitment and efforts in the area of infectious disease.


​​​​​​​1The World Health Organization. New report calls for urgent action to avert antimicrobial resistance crisis. April 29, 2019. Last accessed December 2020.

​​​2Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: Last accessed December 2020.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories